Therapeutic Solutions International Identifies Novel Biological Pathway Utilized by its Phase III Adult Stem Cell Product JadiCell™ to Stimulate Healing of Injured Lung Tissue
Therapeutic Solutions International announced significant advancements in their JadiCell™ adult stem cell product, which promotes the regeneration of lung tissue. Recent experiments in mice show that intravenous JadiCells preserve lung function and stimulate lung repair cells, offering hope for chronic conditions like Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF). The company is preparing to initiate a Phase III clinical trial for COVID-19-related lung failure, aiming to further validate the therapeutic potential of JadiCells.
- Data indicates JadiCell therapy promotes lung tissue regeneration.
- Intravenous JadiCells preserve lung function in preclinical trials.
- Potential expansion into treatment for COPD and IPF.
- Preparations for Phase III COVID lung failure trial are underway.
- None.
Company Plans to Leverage Current FDA Clinical Trial Clearance to Accelerate Entry into Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
In a series of experiments, lung injury was induced in mice by administration of inflammatory stimuli representative of bacterial infection, trauma, (TLR-4 agonists) or viral infection (TLR-3 agonists). Intravenous delivery of JadiCells resulted in preservation of lung function and increased multiplication of cells believed to be the “repair cells” of the lung. Importantly, depletion of T regulatory cells negated the therapeutic effects of the JadiCells.
“Based on my medical experience, the currently published data on the JadiCells, and what I have personally observed from administration under the Right to Try exemption, I believe that these cells represent a paradigm shift in the way we approach lung disease,” said Dr
The newly announced data supports previous patent filings covering the ability of JadiCell not only to prevent inflammation, cytokine storm, and lung injury, but also to stimulate existing lung stem cells to heal damage that has already occurred. Importantly, the observation that T regulatory cells appear to be essential in stimulation of lung healing suggests the possibility that JadiCells induce a long-term beneficial effect. In contrast to cells of the mesenchymal stem cell family, of which JadiCells are a part of, T regulatory cells have the ability to become memory cells which in many cases persist for life.
“The field of cell therapy is the future of medicine, however, in order to maximize their potential benefits, we need to always strive to learn as much about their science as possible,” said Dr.
“As we are finalizing preparations for initiation of our Phase III COVID-19 lung failure clinical trial, I am proud to report that significant basic scientific progress is being made, which is setting the foundation for possible expansion into COPD and IPF which represent a significant unmet medical need,” said
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005646/en/
ir@tsoimail.com
Source:
FAQ
What are the findings of Therapeutic Solutions International regarding JadiCell?
What diseases is Therapeutic Solutions International targeting with JadiCell?
What is the status of the Phase III clinical trial for Therapeutic Solutions International?
How does JadiCell therapy work according to the press release?
What was observed regarding T regulatory cells in the study?
